CR20110046A - Amidofenoxiindazoles utiles como inhibidores de c-met - Google Patents

Amidofenoxiindazoles utiles como inhibidores de c-met

Info

Publication number
CR20110046A
CR20110046A CR20110046A CR20110046A CR20110046A CR 20110046 A CR20110046 A CR 20110046A CR 20110046 A CR20110046 A CR 20110046A CR 20110046 A CR20110046 A CR 20110046A CR 20110046 A CR20110046 A CR 20110046A
Authority
CR
Costa Rica
Prior art keywords
useful
amidophenoxyindazols
met inhibitors
inhibitors
met
Prior art date
Application number
CR20110046A
Other languages
English (en)
Inventor
Li Tiechao
Andrew Pobanz Mark
Shih Chuan
Wu Zhipei
Jennifer Yan Wei
Zhong Boyu
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of CR20110046A publication Critical patent/CR20110046A/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Hydrogenated Pyridines (AREA)

Abstract

La presente invención se refiere a compuestos de amidofenoxiindazol útiles en el tratamiento de cáncer.
CR20110046A 2008-07-24 2011-01-24 Amidofenoxiindazoles utiles como inhibidores de c-met CR20110046A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US8329408P 2008-07-24 2008-07-24
US8508208P 2008-07-31 2008-07-31
US10865908P 2008-10-27 2008-10-27

Publications (1)

Publication Number Publication Date
CR20110046A true CR20110046A (es) 2011-04-27

Family

ID=41010247

Family Applications (1)

Application Number Title Priority Date Filing Date
CR20110046A CR20110046A (es) 2008-07-24 2011-01-24 Amidofenoxiindazoles utiles como inhibidores de c-met

Country Status (35)

Country Link
US (2) US8030302B2 (es)
EP (1) EP2310382B1 (es)
JP (1) JP5414794B2 (es)
KR (1) KR101334456B1 (es)
CN (1) CN102105462B (es)
AR (1) AR074632A1 (es)
AT (1) ATE546444T1 (es)
AU (1) AU2009274256B2 (es)
BR (1) BRPI0916286B8 (es)
CA (1) CA2731773C (es)
CL (1) CL2011000134A1 (es)
CO (1) CO6351737A2 (es)
CR (1) CR20110046A (es)
CY (1) CY1112595T1 (es)
DK (1) DK2310382T3 (es)
DO (1) DOP2011000009A (es)
EA (1) EA018385B1 (es)
EC (1) ECSP11010778A (es)
ES (1) ES2379587T3 (es)
HR (1) HRP20120202T1 (es)
IL (1) IL210490A (es)
JO (1) JO2788B1 (es)
MA (1) MA32594B1 (es)
MX (1) MX2011000925A (es)
MY (1) MY163852A (es)
NZ (1) NZ590013A (es)
PE (1) PE20110150A1 (es)
PL (1) PL2310382T3 (es)
PT (1) PT2310382E (es)
RS (1) RS52261B (es)
SI (1) SI2310382T1 (es)
SV (1) SV2011003816A (es)
TW (1) TWI365185B (es)
WO (1) WO2010011538A1 (es)
ZA (1) ZA201100219B (es)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2740746A1 (en) 2008-10-14 2010-04-22 Ning Xi Compounds comprising a spiro-ring and and methods of use
EP2408300B1 (en) 2009-03-21 2016-05-11 Sunshine Lake Pharma Co., Ltd. Amino ester derivatives, salts thereof and methods of use
RU2568258C2 (ru) 2011-02-28 2015-11-20 Саншайн Лейк Фарма Ко., Лтд Замещенные соединения хинолина и способы их использования
US8962623B2 (en) * 2011-03-04 2015-02-24 Locus Pharmaceuticals, Inc. Aminopyrazine compounds
KR20130118612A (ko) * 2012-04-20 2013-10-30 (주)네오믹스 신규한 아미노피리딘 유도체 및 이의 용도
CN104334581B (zh) * 2012-05-09 2018-02-02 伊莱利利公司 抗‑c‑Met抗体
WO2014134313A1 (en) * 2013-02-27 2014-09-04 Array Biopharma Inc. Intermediates for use in the preparation of indazole derivatives and processes for the preparation thereof
CN104140393B (zh) * 2013-12-10 2016-09-21 郑州泰基鸿诺医药股份有限公司 一种芳环/芳杂环叔丁醇酯类化合物的制备方法
EP3134088B1 (en) 2014-04-22 2019-04-10 Calitor Sciences, LLC Bicylcic pyrazolone compounds and methods of use
TW201716085A (zh) * 2015-08-12 2017-05-16 應克隆公司 癌症之組合療法
WO2017180462A1 (en) 2016-04-15 2017-10-19 Eli Lilly And Company Combination of ramucirumab and merestinib for use in treatment of colorectal cancer
US11827688B2 (en) 2016-06-02 2023-11-28 Immunocore Limited Dosing regimen for GP100-specific TCR—anti-CD3 SCFV fusion protein
JP2019525934A (ja) * 2016-07-29 2019-09-12 イーライ リリー アンド カンパニー 癌の治療に使用するためのメレスチニブおよび抗pd−l1または抗pd−1阻害剤を用いた組み合わせ治療
CN108069938A (zh) * 2016-11-15 2018-05-25 中国药科大学 2,4-二取代吡啶类化合物及其制备方法和应用
EP3541384A1 (en) * 2016-11-16 2019-09-25 Eli Lilly and Company Treatment of cancer with exon 14 skipping mutation(s) or exon 14 skipping phenotype
ES2866348T3 (es) 2016-11-16 2021-10-19 Lilly Co Eli Terapia de combinación para el cáncer con mutación o mutaciones de omisión del exón 14 o fenotipo de omisión del exón 14
CN107311983A (zh) * 2017-07-06 2017-11-03 北京万全德众医药生物技术有限公司 吲哚类小分子c‑met抑制剂
CN107382968A (zh) * 2017-07-06 2017-11-24 北京万全德众医药生物技术有限公司 一种吲哚类c‑Met抑制剂的制备方法
US10180422B1 (en) 2017-08-22 2019-01-15 Scripps Health Methods of treating a neuroendocrine tumor
EP3480201A1 (en) 2017-11-06 2019-05-08 Oncostellae, S.L. New analogs as androgen receptor and glucocorticoid receptor modulators
JP7377798B2 (ja) 2017-11-24 2023-11-10 南京明徳新薬研発有限公司 c-MET/AXL阻害剤としてのウラシル系化合物
US20210177828A1 (en) * 2018-01-17 2021-06-17 Nanjing Transthera Biosciences Co., Ltd. Tam family kinase /and csf1r kinase inhibitor and use thereof
ES2980476T3 (es) 2018-03-08 2024-10-01 Wellmarker Bio Co Ltd Derivados de tienopiridina y composición farmacéutica que los contiene
ES2985569T3 (es) * 2018-08-24 2024-11-06 Transthera Sciences Nanjing Inc Nuevo inhibidor de derivado de quinolina
WO2020048455A1 (zh) 2018-09-03 2020-03-12 泰励生物科技(上海)有限公司 用作抗癌药的trk抑制剂
WO2021045279A1 (ko) 2019-09-06 2021-03-11 웰마커바이오 주식회사 바이오마커 기반 치료용 조성물
CN117355533A (zh) * 2021-06-22 2024-01-05 株式会社Lg化学 作为蛋白激酶抑制剂的新型化合物
WO2023110936A1 (en) 2021-12-14 2023-06-22 Netherlands Translational Research Center Holding B.V Reversible macrocyclic kinase inhibitors

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NO155316C (no) * 1982-04-23 1987-03-11 Sintef Fremgangsmaate for fremstilling av magnetiske polymerpartikler.
US5484681A (en) * 1994-10-31 1996-01-16 Xerox Corporation Conductive composite particles and processes for the preparation thereof
IL114149A0 (en) * 1995-06-14 1995-10-31 Yeda Res & Dev Modified avidin and streptavidin molecules and use thereof
US5747577A (en) * 1995-12-27 1998-05-05 Xerox Corporation Conductive particles containing carbon black and processes for the preparation thereof
DE10046029A1 (de) 2000-09-18 2002-03-28 Bayer Ag Indazole
CN1258091C (zh) * 2001-05-18 2006-05-31 爱赐爱儿股份有限公司 免疫测定
US6956084B2 (en) * 2001-10-04 2005-10-18 Bridgestone Corporation Nano-particle preparation and applications
JP2004067703A (ja) * 2002-04-24 2004-03-04 Japan Science & Technology Corp 架橋ポリマー、微粒子および製造方法
US7192780B2 (en) * 2002-10-23 2007-03-20 Evident Technologies Fluorescent lifetime biological detection and imaging using water-stable semiconductor nanocrystals
US7737153B2 (en) 2002-10-28 2010-06-15 Bayer Schering Pharma Aktiengesellschaft Heteroaryloxy-substituted phenylaminopyrimidines as rho-kinase inhibitors
CA2532711C (en) * 2003-07-17 2013-07-23 Dynal Biotech Asa Coating of porous, surface functionalized, superparamagnetic crystal-containing polymer particles with polyisocyanate/diol and/or epoxide monomers
US7163998B2 (en) * 2003-09-09 2007-01-16 Eastman Kodak Company Stabilized polymer beads and method of preparation
US20050288290A1 (en) 2004-06-28 2005-12-29 Borzilleri Robert M Fused heterocyclic kinase inhibitors
US7439246B2 (en) 2004-06-28 2008-10-21 Bristol-Myers Squibb Company Fused heterocyclic kinase inhibitors
JO2787B1 (en) 2005-04-27 2014-03-15 امجين إنك, Alternative amide derivatives and methods of use
HUE030390T2 (en) 2005-12-21 2017-05-29 Janssen Pharmaceutica Nv Triazolopyridazines as tyrosine kinase modulators
MX2008011220A (es) 2006-03-07 2008-09-11 Array Biopharma Inc Compuestos de pirazol heterobiciclicos y metodos de uso.
EP2230264B1 (en) * 2006-06-29 2019-10-09 Life Technologies AS Particles containing multi-block polymers
PE20080403A1 (es) 2006-07-14 2008-04-25 Amgen Inc Derivados heterociclicos fusionados y metodos de uso
CA2667428A1 (en) 2006-10-23 2008-05-02 Sgx Pharmaceuticals, Inc. Bicyclic triazoles as protein kinase modulators
PL2170785T3 (pl) 2007-06-27 2018-12-31 Arkema Inc. Sposób wytwarzania fluorowodoroolefin

Also Published As

Publication number Publication date
JP2011529054A (ja) 2011-12-01
BRPI0916286B8 (pt) 2021-05-25
WO2010011538A1 (en) 2010-01-28
US20100022529A1 (en) 2010-01-28
AU2009274256B2 (en) 2013-07-11
ES2379587T3 (es) 2012-04-27
USRE43878E1 (en) 2012-12-25
ECSP11010778A (es) 2011-02-28
ZA201100219B (en) 2012-06-27
DK2310382T3 (da) 2012-03-26
JO2788B1 (en) 2014-03-15
HK1155172A1 (en) 2012-05-11
PE20110150A1 (es) 2011-03-07
TWI365185B (en) 2012-06-01
JP5414794B2 (ja) 2014-02-12
HRP20120202T1 (hr) 2012-03-31
IL210490A0 (en) 2011-03-31
EP2310382B1 (en) 2012-02-22
SV2011003816A (es) 2011-03-17
MX2011000925A (es) 2011-03-21
EA018385B1 (ru) 2013-07-30
MA32594B1 (fr) 2011-09-01
NZ590013A (en) 2012-06-29
CN102105462A (zh) 2011-06-22
US8030302B2 (en) 2011-10-04
CY1112595T1 (el) 2016-02-10
EP2310382A1 (en) 2011-04-20
PT2310382E (pt) 2012-04-11
PL2310382T3 (pl) 2012-07-31
CL2011000134A1 (es) 2011-07-08
CO6351737A2 (es) 2011-12-20
ATE546444T1 (de) 2012-03-15
AR074632A1 (es) 2011-02-02
BRPI0916286B1 (pt) 2019-10-08
SI2310382T1 (sl) 2012-04-30
CA2731773A1 (en) 2010-01-28
KR20110022691A (ko) 2011-03-07
CA2731773C (en) 2013-03-12
EA201170252A1 (ru) 2011-06-30
AU2009274256A1 (en) 2010-01-28
DOP2011000009A (es) 2011-03-31
KR101334456B1 (ko) 2013-11-29
IL210490A (en) 2013-06-27
RS52261B (sr) 2012-10-31
TW201006817A (en) 2010-02-16
MY163852A (en) 2017-10-31
CN102105462B (zh) 2014-07-23

Similar Documents

Publication Publication Date Title
DOP2011000009A (es) Amidofenoxiindazoles utiles como inhibidores de c-met
ECSP11011441A (es) Compuestos vinil indazolilo
MA32938B1 (fr) Composes organiques
HN2007015177A (es) Derivados de triazolopirazina
UY31432A1 (es) Compuestos de diarilhidantoina
BRPI1010795A2 (pt) compostos antivirais
CR20120295A (es) Triazolopiridinas
CR20120659A (es) Derivados de piperidinona como inhibidores mdm2 para el tratamiento de cáncer
BR112012019302A2 (pt) imidazo[1,2-b][1,2,4]triazinas como inibidores de c-met
CR20120297A (es) Espironucleósidos uracílicos oxetánicos
CR20140468A (es) Inhibidores de diacilglicerol aciltransferasa 2
GT200800075S (es) Diseño de embudo
EP2332187A4 (en) PHOSPHOR CONVERSED LED
CR20110686A (es) Pirimidinonas como ihnibidores de pi3k
PA8841901A1 (es) Compuestos orgánicos
UY33929A (es) Compuestos de ciclohexilo tetrasustituido como inhibidores de quinasas
CR20120641A (es) Compuestos macrocìclicos como inhibidores de quinasa trk
BRPI0916375A2 (pt) compostos orgânicos como inibidores de smo
UY34165A (es) ?compuestos aldh-2 mitocondriales humanos para el tratamiento de la adicción?.
CO6511220A2 (es) Quinazolinas como inhibidores de los canales iónicos de potasio
UY32553A (es) Nuevos derivados de la pirrolidinadiona espiroheterocíclicos 3-sustituidos
CR20150132A (es) Profármacos de aminoquinazolina inhibidora de cinasa
UA106889C2 (uk) Похідні n1-ацил-5-фторпіримідинону
GT200700074A (es) Fungicidas
CR20140531A (es) Derivados de ariletinilo